Skip to main content
SOMNOMED LIMITED logo

SOMNOMED LIMITED — Investor Relations & Filings

Ticker · SOM ISIN · AU000000SOM1 LEI · 529900NFR8QFOLJGP577 ASX Manufacturing
Open in API
Filings indexed 982 across all filing types
Latest filing 2025-04-06 Regulatory Filings
Country AU Australia
Listing ASX SOM

About SOMNOMED LIMITED

https://somnomed.com

SomnoMed Limited specializes in the development and manufacture of diagnostic and treatment solutions for sleep-related breathing disorders, primarily obstructive sleep apnea (OSA). The company is recognized for its Continuous Open Airway Therapy (COAT), which utilizes custom-fitted oral appliances to maintain an open airway during sleep. Its flagship product line, SomnoDent, offers a range of mandibular advancement devices designed to improve patient compliance and comfort compared to traditional continuous positive airway pressure (CPAP) therapy. SomnoMed focuses on clinical research and technological innovation to provide effective, non-invasive alternatives for patients suffering from mild to moderate OSA and snoring. The company serves a global market, collaborating with sleep dentists and physicians to deliver personalized treatment options that enhance long-term health outcomes and quality of life for individuals with sleep-disordered breathing.

Recent filings

Filing Released Lang Actions
United States of America tariff update 1 page 239.5
Regulatory Filings Classification · 95% confidence The document is a short announcement (2132 characters) providing an update on the impact of new US tariffs on SomnoMed's operations and reaffirming previous FY25 financial guidance. It does not contain detailed financial statements or comprehensive analysis typical of an Interim/Quarterly Report or Annual Report. It also does not announce a new financing, management change, or legal proceeding. The document is an operational update related to tariffs and guidance reaffirmation, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-04-06 English
Half Yearly Report and Accounts 18 pages 4.7MB
Regulatory Filings
2025-02-27 English
FY25 Half Year Results 3 pages 204.5KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'FY25 Half Year Results' and provides detailed financial data for the half year period ended 31 December 2024, including revenue, EBITDA, cash balances, operational highlights, regional performance, and outlook. It contains substantive financial data and analysis for a period shorter than a full fiscal year, which aligns with the definition of an Interim / Quarterly Report (IR). The document is 6521 characters long, which is sufficient to be a full report rather than a brief announcement. There is no indication that this is merely an announcement of a report or a certification. Therefore, the document fits best under the Interim / Quarterly Report (IR) category. H1 2025
2025-02-27 English
Investor presentation 19 pages 1.2MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation Half Year 2025 Results February 2025' and contains detailed financial data including revenue, EBITDA, cash flow, balance sheet summaries, and operational updates for the half year ending December 2024. It includes forward-looking statements, financial metrics, regional highlights, manufacturing updates, leadership team introductions, and FY25 guidance. The document is structured as a presentation aimed at investors, focusing on financial performance, strategy, and outlook rather than being a formal regulatory filing like an annual or interim report. The length is substantial (over 13,000 characters) and contains detailed financial and operational information typical of an investor presentation. Therefore, the appropriate classification is 'Investor Presentation' (IP).
2025-02-27 English
H1FY25 Financial Results webinar details 1 page 151
Report Publication Announcement Classification · 95% confidence The document is a short announcement (1447 characters) stating that SomnoMed's half-year financial results and investor presentation for H1FY25 will be released on a future date. It includes details about a webinar for management's presentation and Q&A session. There is no actual financial data or detailed report content included, only a notice of the upcoming release and event. According to the 'MENU VS MEAL' rule, this is an announcement about a report, not the report itself. Therefore, the appropriate classification is Report Publication Announcement (RPA).
2025-02-10 English
Notification regarding unquoted securities - SOM 7 pages 21.6KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and contains detailed information about the issuance of unquoted securities under an employee incentive scheme. It includes specifics such as the number of securities issued, issue dates, security descriptions, and references to ASX listing rules. The document is a formal notification of a securities issue event rather than a financial report, earnings release, or management discussion. It fits the category of announcements regarding new share issues or capital changes. Therefore, the document is best classified as a Share Issue/Capital Change announcement (SHA). The document length (7383 characters) and content confirm it is not a brief report publication announcement or a regulatory filing fallback. Confidence is high due to clear and specific content matching the SHA category.
2025-01-28 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.